论文部分内容阅读
采用自身对照的研究方法,选择二甲双胍联合其他降糖药物治疗后血糖控制欠佳的超重或肥胖T_2DM患者,给予序贯剂量的艾塞那肽联合二甲双胍治疗16周。结果 PPG降低(4.92±5.47)mmol/L、HbA_(1c)下降(1.05±0.55)%(P<0.05),FPG(P>0.05);与治疗4周时相比,HOMA-%B明显升高,HbA_(1c)有所下降(P<0.05),△HOMA-%B与△HbA_(1c)呈负相关;W、BMI、Wt与基线相比,(P<0.05)。结论应用艾塞那肽联合二甲双胍治疗超重或肥胖T_2DM患者,可降低PPG和HbA_(1c);提高HOMA-%B,降低W、BMI、Wt。
A self-controlled study was conducted to compare the efficacy and safety of metformin with metformin and other methotrexate-treated over-weight or obese T 2DM patients treated with other antidiabetic drugs for 16 weeks. Results The levels of PPG decreased (4.92 ± 5.47) mmol / L, HbA 1c decreased 1.05 ± 0.55% (P <0.05), and FPG (P> 0.05) (P <0.05). △ HOMA-% B was negatively correlated with △ HbA_ (1c); W, BMI and Wt were significantly lower than those of baseline (P <0.05). Conclusions Exenatide plus metformin can reduce PPG and HbA_ (1c), increase HOMA-% B and decrease W, BMI and Wt in overweight or obese T2DM patients.